Innovative Cell Therapies Carisma Therapeutics is at the forefront of developing macrophage-based immunotherapies with multiple programs in clinical trials, highlighting a significant opportunity to engage with pharmaceutical companies seeking next-generation cancer treatments.

Expanding Pipeline Beyond cancer, Carisma is progressing into liver-fibrosis treatment with an IND projected for 2026, opening avenues for collaborations with specialists in chronic liver diseases and fibrosis-related conditions.

Clinical Stage Focus As a clinical-stage company with multiple therapies in development, Carisma is seeking strategic partnerships to accelerate clinical development and expand their therapeutic portfolio, providing potential sales opportunities for biotech and pharma collaborators.

Funding and Growth With over 50 million dollars in funding and revenue between 10 to 25 million dollars, Carisma has the financial backing to support partnerships and licensing deals that can enhance their pipeline and market reach.

Industry Engagement Carisma actively participates in prominent industry events such as conferences, indicating openness to networking and partnership opportunities with investors, researchers, and biotech players aiming to advance cell therapy innovations.